For the year ending 2025-12-31, COGT made $348,052K in revenue. -$329,029K in net income. Net profit margin of -94.53%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Net unrealized gains (losses) on marketable securities | -92 | |||
| Total other comprehensive income (loss) | -92 | |||
| Research and development | 269,780 | |||
| General and administrative | 63,583 | |||
| Total operating expenses | 333,363 | |||
| Loss from operations | -333,363 | |||
| Change in fair value of cvr liability | 0 | |||
| Interest income | 14,689 | |||
| Interest expense | 3,062 | |||
| Loss on debt extinguishment | -7,181 | |||
| Other income (expense), net | -20 | |||
| Total other income, net | 4,426 | |||
| Net loss | -328,937 | |||
| Comprehensive loss | -329,029 | |||
| Earnings per share, basic, total | -538.96 | |||
| Earnings per share, diluted, total | -538.96 | |||
| Weighted average number of shares outstanding, basic, total | 67,600 | |||
| Weighted average number of shares outstanding, diluted, total | 67,600 | |||
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)